Analysing Modafinil Analogues: Why GC Misleads
Modafinil, adrafinil, CRL-40,940 and CRL-40,941 degrade in the GC injector. What the literature says about method selection for this family.
-
-
The Oral Peptide Revolution: How Drug Designers Are Breaking the Bioavailability Barrier
Icotrokinra, approved in March 2026, is a 13-amino-acid cyclic peptide taken as a daily tablet that beat both placebo and an oral small molecule in Phase 3. It works with an oral bioavailability of a few tenths of one percent and no absorption enhancer.
-
Is TFA Really an Inert Peptide Counterion? New Evidence Challenges a Long-Standing Assumption
A September 2026 Nature Communications study reports that trifluoroacetate, the counterion on most synthetic peptides, binds PPAR-alpha and produces metabolic effects in mice, including when it arrives attached to unrelated peptides. What that means for experimental design.
-
The Solvent Problem: Peptide Manufacturing Is Scaling Into a Regulatory Squeeze
GLP-1 demand pushed peptide synthesis to metric-ton scale. At the same moment the EU restricted DMF and added DMAc and NEP to Annex XVII. The chemistry that makes peptides runs on solvents Europe is phasing out.
-
Designed Peptides in August 2026: Three Papers, Three Different Meanings of “Designed”
In one month: computationally designed antimicrobial nanopores that work in mice, an engineered peptide nanopore that detects single α-synuclein species, and LLM-assisted design of cell-penetrating peptides. The three are not the same kind of result.
-
The Same Peptide, Injected and Swallowed: What Zenagamtide’s Two Trials Cost to Compare
Novo Nordisk ran one peptide two ways in the same trial network. The top oral arm received about nine times more drug per week than the injected arm — for a smaller effect. A rare direct measurement of the oral peptide tax.
-
The Hormone That Kept Turning Into Amyloid: Why Amylin Took Thirty Years to Become a Drug
Human amylin forms amyloid fibrils in the pancreas, which is why it was undruggable. Three proline substitutions borrowed from rat amylin fixed it. And its receptor is not a receptor at all.
-
GHK-Cu + KPV Blend: Naming, Formulations and What the COA Should Show
Search for the two-peptide blend of GHK-Cu and KPV and you will not find one product. You will find at least eight different names for what is, in most cases, the same vial — and two different formulations sold under those names without anyone flagging the difference. This is a nomenclature problem, not a chemistry…
-
What Is GLP-4? A Search of the Literature for a Peptide That Does Not Appear in It
A term has been circulating in grey-market listings: GLP-4, presented as the successor to the incretin peptides that came before it. Before assessing any such claim, a laboratory needs a prior question answered — does the molecule exist in the published record at all? We searched PubMed and the clinical trial registries on 2 August…
-
Omegatide: a name for a stack, not a molecule
A name arrives before the data does. Omegatide appears in vendor listings and forum threads as though it were a compound with a history, and readers reasonably assume that a name of that shape — the -tide ending, the single word — points to a single characterised molecule. It does not. Searching PubMed on 2…
